18 Jul 2016 07:00
Grant of share options to Chief Financial Officer
18 July 2016
Pursuant to the announcement of 24 May 2016, Silence Therapeutics plc ("Silence" or the "Company"), AIM: SLN, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms that David Ellam starts today as Chief Financial Officer and a director on the Board of the Company.
David has today been awarded 200,000 options, vesting after 3 years and at a strike price of 110.62p, being the closing price of the Company's shares on Friday 15 July 2016.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. | Details of PDMR / person closely associated with them ("PCA") | ||
a) | Name | David Ellam | |
b) | Position / status | Chief Financial Officer | |
c) | Initial notification / amendment | Initial notification | |
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument | Options over ordinary shares | |
b) | Nature of the transaction | Grant of options | |
c) | Price(s) and volume(s) | Price (s) | Volume(s) |
110.62p | 200,000 | ||
d) | Aggregated information - Aggregated volume - Price | N/A - single transaction
| |
e) | Date of the transaction | 18 July 2016 | |
f) | Place of the transaction | London Stock Exchange, AIM | |
Enquiries:
Silence Therapeutics plc
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Tel: +44 (0)20 3457 6900
Canaccord Genuity Limited (Nominated Adviser and Joint Broker)
Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel
Tel: +44 (0)20 7523 8350
Peel Hunt LLP (Joint Broker)
James Steel/Oliver Jackson
Tel: +44 (0)20 7418 8900
Media Enquiries:
FTI Consulting
Simon Conway/Brett Pollard/Stephanie Cuthbert
Tel: +44 (0) 20 3727 1000
Notes to Editors:
About Silence Therapeutics Plc
Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics.